Literature DB >> 9894881

Increased activity of surviving locus ceruleus neurons in Alzheimer's disease.

W J Hoogendijk1, M G Feenstra, M H Botterblom, J Gilhuis, I E Sommer, W Kamphorst, P Eikelenboom, D F Swaab.   

Abstract

In Alzheimer's disease (AD) there is neuronal loss in the locus ceruleus (LC), and the noradrenergic system may be even more affected in depressed AD patients. However, this neuronal loss may go together with an increase in activity of the remaining noradrenergic neurons. We prospectively evaluated 16 AD patients (6 depressed, 5 transiently depressed, and 5 nondepressed) and 10 controls. We determined norepinephrine and its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in various brain areas, and compared these data with previously established neuron numbers in the LC in the same patients. We could not confirm earlier studies reporting lower norepinephrine concentrations in depressed than in nondepressed dementia patients. The mean norepinephrine concentrations in AD patients were significantly lower than those in control patients, whereas the mean concentrations of MHPG were not different. Moreover, we found significant inverse relationships between the number of remaining pigmented LC neurons and the MHPG/norepinephrine ratio in the frontal cortex and LC. These data are the first to provide direct evidence for the hypothesis that remaining LC neurons are activated to compensate for decreased cerebral norepinephrine levels in AD, by demonstrating that the MHPG/norepinephrine ratio is significantly higher in AD, indicating increased metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9894881     DOI: 10.1002/1531-8249(199901)45:1<82::aid-art14>3.0.co;2-t

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 2.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

4.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 5.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

6.  Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats.

Authors:  Izzettin Hatip-Al-Khatib; Katsunori Iwasaki; Yoshitaka Yoshimitsu; Takashi Arai; Nobuaki Egashira; Kenichi Mishima; Tomoaki Ikeda; Michihiro Fujiwara
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

7.  Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity.

Authors:  Dayong Wang; G Govindaiah; Ruijie Liu; Vania De Arcangelis; Charles L Cox; Yang K Xiang
Journal:  FASEB J       Date:  2010-04-15       Impact factor: 5.191

Review 8.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

9.  Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.

Authors:  Lucy Y Wang; Jane B Shofer; Kirsten Rohde; Kim L Hart; David J Hoff; Yun H McFall; Murray A Raskind; Elaine R Peskind
Journal:  Am J Geriatr Psychiatry       Date:  2009-09       Impact factor: 4.105

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.